Targeted Temperature Management (TTM) or Therapeutic Hypothermia (TH) is currently one of the most important methods of neuroprotection. It involves lowering a patient's body temperature in order to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow. Periods of insufficient blood flow may be due to cardiac arrest and the occlusion of an artery by an embolism, as in the case of strokes (Andresen et al., 2015).
The mechanisms of action of TTM are varied and can affect many metabolic pathways, inflammation reactions, apoptosis processes, and promote neuronal integrity. Invasive methods to induce TTM are initiated by using a catheter inserted into the inferior vena cava via the femoral vein or non-invasive means. Non-invasive means may utilize a chilled water blanket, torso vest, and leg wraps that are in direct contact with the patient's skin. Studies have demonstrated that patients at risk for ischemic brain injuries have better outcomes if treated with TTM promptly. The major goal of TTM treatment is to achieve the target temperature as quickly as possible. This may take between 3-4 hours after initiating the cooling process. The recommended duration of TTM after reaching the target temperature is at least 24 hours (Koyfman, 2019).
Since antiquity, TTM has been applied therapeutically. Hippocrates, the Greek physician, was historically noted for the Hippocratic Oath and was considered the first modern doctor and advocated the packing of wounded soldiers in snow and ice. Hippocrates felt that placing his bleeding patients in the snow decreased blood flow. Surgeons during the Napoleonic war used the same technique on soon-to-be-amputated limbs. Napoleon's surgeon, Baron Dominque-Jean Larrey, recorded that officers, who were kept closer to the fire, survived less often than the minimally pampered infantrymen. During the 1940s, hypothermia was used to treat pain and retard cancer growth. The 1950s led the way to the use of hypothermia as a means of reducing blood flow to vital organs during surgery.
The first medical article in 1945 described a study on the effects of hypothermia on patients suffering from a severe head injury. In 1950 TTM received its first medical application when it was used in intracerebral aneurysm surgery to create a bloodless operating field. Initially, early research mainly focused on the applications of deep hypothermia when the body's temperature was between 20-25 degrees centigrade (68-77 degrees F). This temperature range had many side effects, which at the time made deep hypothermia impractical in most clinical situations. Today, the temperature range is between 320°c (89.60° f) to 360° c (96.8° f) which has demonstrated fewer side effects and more positive results (AHA, 2019).
During the 1950's more research was done utilizing mild forms of hypothermia. The body temperature was kept between 32° and 34° C (90°-93° F). In the 1980s, animal studies indicated the ability of mild hypothermia to act as a general neuro-protectant following a blockage of blood flow to the brain.
In 2000 according to BBC News, Anna Bgenholm's heart stopped for more than three hours following a skiing accident, and her body temperature dropped to 13.7°c before being resuscitated. According to author and researcher R. Winslow, in 2009, two human studies were published simultaneously in 2002 by M. Holzer in The New England Journal of Medicine. Both studies, one occurring in Europe and the other in Australia, demonstrated the positive effects of mild hypothermia after cardiac arrest.
The American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) endorsed the use of TTM following cardiac arrest. They recommend cooling comatose (lack of meaningful verbal response to verbal commands) adult victims with Return of Spontaneous Circulation (ROSC) after out of hospital Ventricular Fibrillation cardiac arrest to 32 degrees to 34 degrees centigrade for 12 to 24 hours. This situation is also considered when a person suffers an out-of-hospital initial rhythm of PEA or asystole (Andresen et al., 2015).
AHA guidelines state that following a cardiac arrest, when the patient returns to spontaneous circulation (ROSC) and is Comatose, the targeted temperature management should be 32 degrees to 36 degrees centigrade (89.6°-96.8o° F) for at least 24 hours. Note this text's table with Guidelines and recommendations (Callaway et al., 2015).
Healthcare providers are considering TTM for those adult patients who are comatose with Return of Spontaneous Circulation (ROSC) after in-hospital cardiac arrest of any initial rhythm. Presently, a growing percentage of hospitals around the world incorporate the AHA/ILCOR guidelines and include hypothermic therapies in their standard care package for patients suffering from cardiac arrest. AHA states that hemodynamically stable patients with spontaneous mild hypothermia (>33 degrees C) after resuscitation from cardiac arrest should not be actively rewarmed (Koyfman, 2019).
Numerous studies and controlled clinical trials have proven that TTM is one of the most important methods of neuroprotection. Hypothermia after cardiac arrest improves outcomes in various clinical scenarios such as post-cardiac arrest, traumatic brain injury, and spinal cord injury. TTM has been used in other diseases where it has proven to be useful, such as with victims of a stroke and acute liver failure (Koyfman, 2019).
Current indications and contraindications for TTM vary between institutions. Inclusion criteria used by many institutions are:
Exclusions may include:
TTM may independently alter the patient's physiology. Potassium and magnesium levels drop and should be replaced. Other normal findings are low WBC and high PT/APPT and LFTs, which do not require treatment. Blood gas analysis may show low pH and HCO3- and high pCO2 and pO2. Depending on the institution's blood-gas analyzer, these values may or may not be temperature adjusted (Koyfman, 2019).
Drug metabolism is generally slowed, leading to increased half-life and drug accumulation.
ECG and cardiac changes occur with TTM. Patients may become hypotensive, bradycardic and have reduced cardiac output. Atrial fibrillation is also common, although research demonstrated severe dysrhythmias with temperatures below 30C (86F). There can be a prolongation of the PR, QRS, QT intervals and J-waves (Koyfman, 2019).
TTM may induce cold diuresis, leading to volume loss. Although coagulopathy and platelet dysfunction are known side effects of hypothermia, there has been no observed difference in adverse bleeding events following TTM, even in those who underwent Pre-cutaneous Coronary Intervention (PCI) or thrombolysis in the immediate post-arrest period. In patients with intracerebral bleeding, TTM does not increase morbidity or mortality (Koyfman, 2019).
Shivering occurs at a core temperature of approximately 35.5°C (96°F) and may be counterproductive to the induction of cooling. This should be treated because it slows the rate of cooling and increases metabolic activity. Treatment includes adequate sedation, followed by muscle paralysis if needed. This treatment could be an uncomfortable treatment modality, and therefore adequate sedation and analgesia must be maintained throughout the hypothermia protocol until the patient has been rewarmed and has returned to normothermia. According to the Swedish Council of CPR, short-acting medications are preferred due to the frequently reduced clearance of these medications in this patient population.
Rewarming should be initiated 12-24 hours after TTM initiation. It should occur slowly at a rate of 0.25°-0.5o°C per hour until the patient reaches normothermia. Rapid rewarming increases the risk of significant complications, including hypotension from substantial vasodilation, hypoglycemia, and hyperkalemia (Koyfman, 2019).
TTM is effective in five primary categories of medical events:
Birth Asphyxia caused by a reduction in blood or oxygen supply to a baby's brain during birth is a major cause of death and brain damage. It occurs in approximately 1 per 1000 births and causes around 20% of all cerebral palsy cases.
Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P., in 2007 found that brain hypothermia, induced by cooling a baby to around 33 degrees C for 3 days after birth, has recently proven to be the only medical intervention that reduces brain damage and improves an infant's chance of normal survival after birth asphyxia.
TTM for neonatal encephalopathy has been proven to improve outcomes for newborn infants affected by perinatal hypoxia-ischemia, hypoxic-ischemic encephalopathy or birth asphyxia. Whole-body or selective head cooling to 33°-34° C (91°-93° F), begun within 6 hours of birth and continued for 72 hours, significantly reduces mortality and reduces cerebral palsy and neurological deficits in survivors (Mrelashvili et al., 2015).
The optimal duration of brain cooling in the human newborn has not been established.
In selective head cooling, a cap (Cool Cap) with channels for circulating cold water is placed over the infant's head, and a pumping device facilitates the continuous circulation of cold water. Nasopharyngeal or rectal temperature is maintained at 34°-35°C for 72 hours (Jacobs et al., 2013).
In whole-body hypothermia, the infant is placed on a commercially available cooling blanket, through which circulating cold water flows so that the desired level of hypothermia is reached quickly and maintained for 72 hours. Rewarming is a critical period, and in clinical trials, rewarming should be carried out gradually over 6-8 hours (Jacobs et al., 2013).
A major contributor to global child mortality and morbidity is neonatal encephalopathy after perinatal hypoxic-ischemic insult. Brain injury in term infants due to hypoxic-ischemic insult is a complex process evolving over hours to days. This time frame provides a unique window of opportunity for neuroprotective treatment interventions. Neuroimaging, brain monitoring techniques, and tissue biomarkers have improved the ability to diagnose, monitor, and care for newborn infants with neonatal encephalopathy. This imaging helps to predict their outcome (Jacobs et al., 2013).
Challenges remain in the early identification of infants at risk for neonatal encephalopathy, the timing and extent of hypoxic-ischemic brain injury, and optimal management and treatment duration. TTM is the most promising neuroprotective intervention for infants with moderate to severe neonatal encephalopathy after perinatal asphyxia and has been incorporated in many neonatal intensive care units in developed countries (Mrelashvili et al., 2015).
Presently, only 1 in 6 babies with encephalopathy benefit from TTM. Many infants still develop significant adverse outcomes. In order to enhance the outcome, specific diagnostic predictors are needed to identify patients likely to benefit from hypothermia treatment. Studies are being done to determine the efficacy of combined therapeutic strategies with hypothermia therapy to achieve the maximal neuroprotective effect.
Uncertainties exist regarding mild to moderate hypothermia as a safe and effective neuroprotective intervention for newborns who have sustained a perinatal hypoxic-ischemic insult resulting in encephalopathy. Completing ongoing trials worldwide and long-term follow-up of survivors is vital to evaluate whether widespread implementation should be initiated or if this action is premature.
Cardiac arrest (CA) is associated with high mortality and causes neurological dysfunction in the survivors. A decrease in metabolism in the brain from TTM may be one of the most important mechanisms of neuroprotection (CDC, 2016).
|2015 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care||Comatose (i.e., lack of meaningful response to verbal commands) adult patient with ROSC after out-of-hospital ventricular fibrillation or pulse-less ventricular tachycardia (pVT) cardiac arrest should undergo targeted temperature management (TTM) with goal temperature 32-36°C (89.6-96.8°F) for at least 24h (class I, level of evidence B).|
Comatose adult patients with ROSC after in-hospital cardiac arrest of any initial rhythm or after out-of-hospital cardiac arrest with an initial rhythm of pulseless electric activity or asystole should undergo targeted temperature management (TTM) with goal temperature 32-36°C (89-6-96-8°F) for at least 24 h (class I, level of evidence C).
|2015 Recommendations from the International Liaison Committee on Resuscitation||Targeted temperature management with goal temperature 32-36°C (89.6-96-8°F) for at least 24 h should be part of a standardized treatment strategy for comatose survivors of cardiac arrest.|
|2010 European Resuscitation Council Guidelines for Resuscitation||Use of therapeutic hypothermia should include comatose survivors of cardiac arrest associated initially with non-shockable rhythms and shockable rhythms. (The lower level of evidence for use after cardiac arrest from non-shockable rhythms is acknowledged.)|
TTM is the term used at hospitals where post-cardiac arrest syndrome or post-arrest organ injury has occurred. The pathophysiology is complex. Hypoperfusion and ischemia cause a cascade of events: disruption of homeostasis, free radical formation and protease activation, among other things. The disruption may continue for hours or days. Hypothermia may slow down this cascade. There are four primary clinical considerations in post-cardiac arrest syndrome.
Patients who receive TTM after resuscitation from cardiac arrest have favorable chances of surviving the event and recovering from good functional status. In TTM, a patient's body temperature is cooled to 33 degrees Celsius following resuscitation from cardiac arrest to slow the brain's metabolism and protect the brain against the damage initiated by the lack of blood flow and oxygenation.
Fewer than 10% of the 300,000 Americans who suffer cardiac arrest each year survive long enough to leave the hospital despite increased use of such measures as faster emergency squads, deployment of automated defibrillators (AED) at airports and other public places, and improvements in cardiopulmonary resuscitation techniques. Treatment with TTM improves survival rates.
Hypothermia proves successful in younger cardiac patients. Young adult patients with genetic heart diseases, such as hypertrophic cardiomyopathy (HCM), substantially benefited from TTM, which could further extend the role of this treatment strategy in new patient populations, according to a scientific presentation at the American College of Cardiology (ACC) Scientific Sessions in New Orleans.
Because of these findings, more support for TTM with the idea of the more widespread availability of TTM and utilization of this process due to its successful outcomes with out-of-hospital cardiac arrest has been initiated in ACLS protocols following a return of circulation when a patient is unconscious. Studies also proved the worth of TTM in younger patients with genetic diseases (Jacobs et al., 2013).
TTM is defined as a body temperature of below 34°C. Differences of opinion exist as to what the goal temperature should be when TTM should be initiated, which cardiac arrest (CA) victims should have the treatment, and so on. Because the pathophysiology for neurologic injury following CA is similar regardless of rhythm or location of arrest, the decision to initiate TTM should be made on an individual patient basis considering the etiology of the arrest, the time before initiation of CPR, duration of CPR prior to ROSC, and overall prognosis based on underlying comorbidities (Jacobs et al., 2013).
Below is the summary of a study demonstrating the feasibility and preliminary safety of combining endovascular hypothermia after stroke with intravenous thrombolysis. Pneumonia was more frequent after hypothermia, but further studies still are needed to determine its effect on patient outcomes and whether it can be prevented. To evaluate the efficacy of TTM for acute stroke, a definitive efficacy trial is necessary (AHA, 2012).
The background and purpose of the study are vital to its reliability: Induced hypothermia is a promising neuroprotective therapy and has demonstrated positive outcomes. The feasibility and safety of hypothermia and thrombolysis after acute ischemic stroke must also be evaluated.
Specific methods used in this study included Intravenous Thrombolysis plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L). This process had to be randomized, and a multicenter trial of hypothermia and intravenous tissue plasminogen activator in patients treated within 6 hours after ischemic stroke was initiated. Enrollment also had to be stratified to the treatment time windows of 0 to 3 and 3 to 6 hours. Patients presenting within 3 hours of symptom onset received standard-dose intravenous alteplase and were randomized to undergo 24 hours of endovascular cooling to 33°C. This treatment was followed by 12 hours of controlled rewarming or normothermia treatment. Those patients presenting between 3 and 6 hours were randomized twice: to receive tissue plasminogen activator or not and to receive hypothermia or not.
Results of the 59 patients who were enrolled in the study demonstrated the following:
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. It has become the most widely used clinical outcome measure for stroke in clinical trials.
The - (mRS) runs from 0-6, from perfect health without symptoms to death.
Conclusion of Study demonstrated:
Most data concerning hypothermia's effectiveness in treating stroke is limited to animal studies. No evidence supporting TTM use in humans and clinical trials has been completed. Completed studies have focused primarily on ischemic stroke as opposed to hemorrhagic stroke. Hypothermia is associated with a lower clotting threshold. In animal studies, hypothermia represented an effective neuroprotectant.
TTM does not seem effective in hemorrhagic stroke (bleeding on the brain). However, there seems to be evidence that hypothermia lowers the body temperature to reduce intracranial pressure and can thus prevent further brain damage by allowing the tissues to heal (CDC, 2016).
Complete spinal cord injuries do not often occur in professional sports but can produce devastating results. The primary injury is serious, but a substantial amount of damage occurs during the secondary response to the injury. Research has focused on reducing this secondary response by slowing inflammation, cell death, or bleeding (Silverman & Scirica, 2016).
Animal studies show the benefit of TTM in traumatic Central Nervous System (CNS) injuries. Clinical trials have shown mixed results regarding the optimal temperature and cooling delay. Achieving therapeutic temperatures of 33° C (91° F) is thought to prevent secondary neurological injuries after severe CNS trauma.
Recent findings indicated that despite experimental evidence, the clinical utility of TTM has still to be conclusively demonstrated in terms of reduced mortality or improved functional recovery after a Traumatic Brain Injury (TBI) (even in pediatric TBI). Current findings support that hypothermia should be initiated as soon as possible, for at least 48 hours. The outcome is worse when barbiturates are part of ICU management.
Currently, available cooling techniques, including pre-hospital cooling protocols, expand and improve clinical management of TTM. The negative effects of the cooling and the rewarming procedure currently overshadow the neuroprotective effects (CDC, 2016).
Neurogenic fever occurs when a patient has an abnormally high fever associated with ischemic events. The higher the temperature in the patient, the more damage occurs to the brain and body. In a patient with either brain trauma or ischemic brain injury combined with a fever, the mortality rate is 14% higher than in patients with normal temperatures (CDC, 2016). Elevated body temperature strongly correlates with an extended stay in the ICU or patients suffering from either ischemic brain injury or brain trauma.
The use of TTM had been well established to improve survival with favorable neurological outcomes in the case of global cerebral ischemia after cardiac arrest or perinatal hypoxia-ischemic insult; however, the efficacy of TTM for treating focal cerebral ischemia had not yet been well studied.
When infants suffer from perinatal asphyxia, it appears that apoptosis is a prominent cause of cell death in which cells activate enzymes that degrade the cells' own nuclear DNA and nuclear and cytoplasmic proteins. Fragments of the apoptotic cell then break off, giving the appearance responsible for the name apoptosis, which can occur under normal or abnormal conditions (Mrelashvili et al., 2015).
TTM for neonatal encephalopathy interrupts the apoptotic pathway. Noted was that cell death is not directly caused by oxygen deprivation but occurs indirectly due to the cascade of subsequent events. Cells need oxygen to create ATP, a molecule used by cells to store energy, and cells need ATP to regulate intracellular ion levels.
ATP is used to fuel both the importation of ions necessary for cellular function and the removal of ions that are harmful to cellular function. Cells need oxygen to manufacture the necessary ATP to regulate ion levels and thus prevent the intracellular environment from approaching the ion concentration of the outside environment. It is not oxygen deprivation that precipitates cell death, but rather without oxygen the cell is unable to make the ATP it needs to regulate ion concentrations and maintain homeostasis.
Even a small drop in temperature encourages cell membrane stability during periods of oxygen deprivation. Therefore, because of this reason, a drop in body temperature helps prevent an influx of unwanted ions during an ischemic insult. By making the cell membrane more impermeable, hypothermia helps prevent the cascade of reactions set off by oxygen deprivation. Moderate dips in temperature strengthen the cellular membrane, helping to minimize any disruption to the cellular environment. By moderating the disruption of homeostasis caused by a blockage of blood flow, many now postulate results in hypothermia's ability to minimize the trauma resultant from ischemic injuries.
Various inflammatory immune responses occur during reperfusion. These inflammatory responses cause increased intracranial pressure, leading to cell injury and cell death in some situations. Hypothermia has been shown to help moderate intracranial pressure and, therefore, to minimize the harmful effects of a patient's inflammatory immune responses during reperfusion. TTM helps to reduce reperfusion injury, damage caused by oxidative stress when the blood supply is restored to the tissue after a period of ischemia. The oxidation that occurs during reperfusion also increases free radical production.
Recent data suggests that even a modest reduction in temperature can function as a neuroprotectant. This data indicates that possibly hypothermia affects pathways that extend beyond a decrease in cellular metabolism. Now the hypothesis centers on the series of reactions following oxygen deprivation, particularly concerning ion homeostasis.
TTM is beneficial in term and late preterm newborns with hypoxic-ischemic encephalopathy. Cooling reduces mortality without increasing major disability in survivors. The benefits of cooling on survival and neurodevelopment outweighed the short-term adverse effects. It was determined that TTM should be instituted in term and late preterm infants with moderate-to-severe hypoxic-ischemic encephalopathy if identified before six hours of age (Mrelashvili et al., 2015).
In patients facing ischemic injury, it is important that to ensure a successful outcome, the administration of TTM should be initiated as soon as possible.TTM remains partially effective when initiated as long as 6 hours after the collapse. Based on the current data from observational studies and randomized control trials, the optimal timing to initiate TTM and achieve the target temperature remains unclear.
There are three phases of TTM: induction, maintenance and rewarming.
Cooling catheters are placed into the inferior vena cava by inserting them into the femoral vein. Cooled saline solution is circulated through a tube or balloon. The saline cools the patient's entire body by cooling the blood as it passes through the heart. Conversely, the catheter method can raise the patient's body temperature if it begins to dip too low.
Adverse effects of this method are associated with an invasive procedure:
Excessive bleeding can become a problem because the patient has a decreased threshold due to lowered temperature. Infection can be deadly in patients already compromised by the original insult. This method can also lead to the development of blood clots and thus cause a pulmonary embolism. Naturally, when using an invasive method, a specialist is needed to insert the catheter via the femoral vein, which may cause a delay in cooling the patient while waiting for a provider certified in this procedure.
Another aspect of TTM is that patients receiving this need to be sedated to prevent shivering since this is a natural response to the drop-in body temperature.
Water blankets are used with cool water, which circulates through the blanket. If a person needs their body temperature lowered, the blankets must cover 80% of the patient's surface area. In order to achieve a faster temperature lowering condition, ice packs can be used. This method is primarily geared at lowering the patient's skin temperature and requires no invasive procedures.
The downside of this method is that the water blankets can leak. This potential leak creates a safety hazard since other electrical equipment may be nearby. Water blankets lower the body temp at a slower rate than other cooling methods. The temperature must be measured by core temperature probes inserted into the body (rectally), and then adjustments in the blanket temperature must be made. If not monitored closely, they can quickly go beyond the target temperature. This increase can lead to spikes in intracranial pressure. There is also a slower induction time versus internal cooling, increased compensatory response, decreased patient access, and discontinuation of cooling for invasive procedures such as cardiac catheterization.
If therapy with water blankets is given with two liters of cold intravenous saline, patients can be cooled to 33 degrees C (91 degrees F) in 65 minutes. Newer water blankets have sophisticated software that prevents warming at too rapid a pace allowing a patient to be rewarmed at a very slow rate of just 0.17 degrees C (0.31 degrees F) an hour when placed in the automatic mode. This technology allows rewarming from 33-37 degrees C (91-99 degrees F) over 24 hours. This method helps to prevent spikes in intracranial pressure. TTM decreases the metabolic rate by 6-7% for every decrease of 1 degree Celsius in temperature.
90% of persons suffering a cardiac arrest never reach the hospital alive. An example of the benefits of TTM is illustrated when a facility in Reno, Nevada, published a study illustrating the benefits of TTM. Abella, B.S. et al. 2005 stated that recovery correlates with body temperature. They discovered that the lower the body temperature is after the event, the greater the possibility for neurologic recovery.
Their case study describes the events of a 56-year-old male smoker with diabetes who suffered a cardiac arrest. CPR was not initiated until paramedics arrived. His first pulse was detected 17 minutes after CPR was started. He was started on TTM protocol 20 minutes after arrival at the Emergency Room. He was treated with body surface cooling pads for 22 hours. The hypothermic target temperature was achieved 6 hours into treatment. Rewarming was started at 22 hours rather than 24 hours because he was showing signs of awakening. Six hours after rewarming began, he responded and 2 hours after that, he was responding to pain.
The following morning, which would have been about 12 hours of normal body temperature, he was opening his eyes to commands and moving. By day 5, after his cardiac arrest, he could follow simple commands. He was treated with physical and speech therapy on the sixth day because of some slowness in his responses. However, by day 11, he had no neurological deficits. He was discharged home on day 12. Several months later, he returned to work.
Another case occurred in Montgomery, Minn., on July 21, 2008. This case involved a 43- year woman who was found unconscious in her home by her twin daughters. They called 911, and after 20 minutes, the ambulance crew was able to restore her heartbeat.
She was taken to the 28-bed Queen of Peace Hospital near New Prague, where an emergency team packed her body in blue ice bags before loading her on a helicopter to Abbott Northwestern Hospital in Minneapolis, about 40 miles away. She was wrapped in a cooling blanket that kept her body temperature at about 92 degrees Fahrenheit before restoring it to normal the following day. Five days later, she regained consciousness and went home five days after that. She returned to work within the month.
The rationale behind the new treatment is that the brain is more resilient than previously believed during the early period after the heart goes down. Of course, the brain cannot live long without the oxygen provided by normal blood flow. But an initial rush of blood to the brain, when resuscitation gets the heart beating again, also kills tissue and is a more important insult.
TTM may independently alter the patient's physiology. Potassium and magnesium levels are seen to drop and should be replaced. Other normal findings are low WBC and high PT/APPT and LFTs, which do not require treatment. Blood gas analysis may show low pH and HCO3- and high pCO2 and pO2. Depending on the institution's blood-gas analyzer, these values may or may not be temperature adjusted. Drug metabolism is generally slowed, leading to increased half-life and drug accumulation.
ECG and cardiac changes occur with TTM. Patients may become hypotensive, bradycardic and have reduced cardiac output. Atrial fibrillation is also common, although research demonstrated severe dysrhythmias with temperatures below 30°C (86°F). There can be a prolongation of the PR, QRS, QT intervals and J-waves.
TTM may induce cold diuresis, leading to volume loss.
Although coagulopathy and platelet dysfunction are known side effects of hypothermia, there has been no observed difference in adverse bleeding events following TTM, even in those who underwent PCI or thrombolysis in the immediate post-arrest period. TTM has not been shown to increase morbidity or mortality in patients with intracerebral bleeding.
Shivering occurs at a core temperature of approximately 35.5°C (96°F) and may be counterproductive to the induction of cooling. Treatment includes adequate sedation, followed by muscle paralysis if needed (Koyfman, 2019).
TTM is one of the most important therapies for providing neuroprotection and can be used in different clinical scenarios. This therapy includes but is not limited to those suffering from neonatal encephalopathy, post-cardiac arrest, stroke, traumatic brain injury, and neurogenic fever.
At normal temperatures, the restoration of blood flow triggers a cascade of inflammatory and other responses over the following minutes and hours, which can injure tissue in the brain and exact a lethal toll. The mechanisms of action of TTM are multiple and varied. TTM can affect many metabolic pathways, inflammation reactions, apoptosis processes, and other pathways.
Today, many think that the success of TTM is due to the multiple mechanisms of action blocking the cascade of ischemia on many levels, which is responsible for its success. Scientists say icing the body slows metabolism and protects the brain from at least some damage caused by the restored blood flow. More and more clinical trials using animals and humans are taking place worldwide. The emergence of more controlled clinical trials evaluating the synergistic effects of TTM in association with other therapies will open the doors so that the survival of those who would have perished now can survive.
CEUFast, Inc. is committed to furthering diversity, equity, and inclusion (DEI). While reflecting on this course content, CEUFast, Inc. would like you to consider your individual perspective and question your own biases. Remember, implicit bias is a form of bias that impacts our practice as healthcare professionals. Implicit bias occurs when we have automatic prejudices, judgments, and/or a general attitude towards a person or a group of people based on associated stereotypes we have formed over time. These automatic thoughts occur without our conscious knowledge and without our intentional desire to discriminate. The concern with implicit bias is that this can impact our actions and decisions with our workplace leadership, colleagues, and even our patients. While it is our universal goal to treat everyone equally, our implicit biases can influence our interactions, assessments, communication, prioritization, and decision-making concerning patients, which can ultimately adversely impact health outcomes. It is important to keep this in mind in order to intentionally work to self-identify our own risk areas where our implicit biases might influence our behaviors. Together, we can cease perpetuating stereotypes and remind each other to remain mindful to help avoid reacting according to biases that are contrary to our conscious beliefs and values.